Compare Teradyne, Inc. (TER) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs GeneDx Holdings Corp — how do they compare? Teradyne, Inc. trades at $404.86 (market cap $59.34B), while GeneDx Holdings Corp trades at $82.4 (market cap $2.44B). The key difference: Teradyne, Inc. is far larger — about 24.3× GeneDx Holdings Corp's market cap, and Teradyne, Inc. pays a 0.14% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TER | WGS | |
|---|---|---|
Market Cap | $59.34B | $2.44B |
Sector | Technology | Technology |
52-Week High | $483.84 | $167.51 |
52-Week Low | $109.30 | $34.51 |
Enterprise Value | $59.09B | $2.48B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $403.6, up 10.55% in 24 hours, near its 52-week high. The stock exhibits bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $2.47 versus $2.09 expected. Revenue growth is accelerating, driven by AI-led demand in semiconductor testing and robotics, with 2026 revenue projected at $4.5 billion. Valuation ratios are elevated, with a P/E of 52.14, reflecting high growth expectations.
The outlook remains positive due to robust AI-driven demand and record earnings, though high valuation poses a risk if growth slows. Analyst consensus is strongly bullish with a $481.63 price target. Key risks include execution challenges in scaling operations and sensitivity to semiconductor cycle downturns. Institutional buying, such as Anson Funds' purchase in Q1 2026, supports momentum.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
